TScan Therapeutics (TCRX) CFO adds principal accounting officer role after VP finance resignation

Rhea-AI Filing Summary

TScan Therapeutics, Inc. reported a leadership change in its finance organization. Leiden Dworak notified the company of his decision to resign as Vice President of Finance and principal accounting officer, effective April 10, 2026, and the company stated there were no disagreements regarding its operations, policies or practices.

The Board appointed Chief Financial Officer Jason A. Amello to also serve as principal accounting officer effective April 10, 2026. The company noted that Mr. Amello will not receive additional compensation for this added role and referenced its May 14, 2025 definitive proxy statement for information on his background, contracts and related party transactions.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

principal accounting officer, principal financial officer, emerging growth company, definitive proxy statement, +1 more

5 terms

principal accounting officer financial

"appointed Jason A. Amello ... as the Company’s principal accounting officer, effective April 10, 2026"

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

principal financial officer financial

"Jason A. Amello, the Chief Financial Officer and principal financial officer of the Company"

The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.

emerging growth company regulatory

"Emerging growth company    On March 31, 2026, Leiden Dworak notified"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

definitive proxy statement regulatory

"definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on May 14, 2025"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

related party transactions financial

"any related party transactions involving Mr. Amello is incorporated by reference herein"

Transactions between a company and people or entities that have close ties to it—such as executives, board members, major shareholders, family members, or related companies—where the parties are not independent. These deals matter to investors because they can create conflicts of interest or hide favorable terms that distort a company’s true profits and risks; think of it like a business buying or selling to a family member instead of using the open market, which can lead to biased prices or undisclosed obligations.

Understanding 8-K Material Events →

false 0001783328 0001783328 2026-03-31 2026-03-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 31, 2026

TSCAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40603		82-5282075
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

830 Winter Street Waltham, Massachusetts		02451
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 857 399-9500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Voting Common Stock, par value $0.0001 per share		TCRX		The Nasdaq Global Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 31, 2026, Leiden Dworak notified TScan Therapeutics, Inc. (the “Company”) of his decision to resign as Vice President of Finance of the Company and principal accounting officer effective April 10, 2026. There were no disagreements between the Company and Mr. Dworak relating to the Company’s operations, policies or practices.

In connection with Mr. Dworak’s resignation, the Board of Directors of the Company appointed Jason A. Amello, the Chief Financial Officer and principal financial officer of the Company, as the Company’s principal accounting officer, effective April 10, 2026.

Information regarding Mr. Amello’s background and business experience, contracts between the Company and Mr. Amello, and any related party transactions involving Mr. Amello is incorporated by reference herein from the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on May 14, 2025. Mr. Amello will not receive any additional compensation for assuming the additional role of principal accounting officer, and no changes have been made to any plans or arrangements in which Mr. Amello participates as a result of this appointment.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						TScan Therapeutics, Inc.
Date: April 2, 2026				By:		/s/ Gavin MacBeath
						Gavin MacBeath
						Chief Executive Officer

FAQ

What leadership change did TCRX report in this 8-K filing?

TScan Therapeutics reported that Leiden Dworak decided to resign as Vice President of Finance and principal accounting officer, effective April 10, 2026. The Board appointed Chief Financial Officer Jason A. Amello to assume the additional role of principal accounting officer on the same effective date.

Did TCRX disclose any disagreements related to the finance executive’s resignation?

The company stated there were no disagreements between TScan Therapeutics and Leiden Dworak relating to the company’s operations, policies or practices. This language indicates the departure is not being characterized as the result of a dispute over how the business is run or governed.

Who will serve as TCRX’s principal accounting officer after April 10, 2026?

After April 10, 2026, Chief Financial Officer Jason A. Amello will also serve as TScan Therapeutics’ principal accounting officer. He already holds the role of principal financial officer, and his background, contracts, and related party transactions are incorporated by reference from the May 14, 2025 proxy statement.

Will Jason A. Amello receive extra compensation for his new responsibilities at TCRX?

TScan Therapeutics disclosed that Jason A. Amello will not receive any additional compensation for assuming the role of principal accounting officer. The company also indicated there are no changes to any existing plans or arrangements in which he participates as a result of this appointment.

Where can investors find more background on TCRX CFO Jason A. Amello?

The company directed readers to its definitive proxy statement on Schedule 14A filed May 14, 2025. That proxy statement contains information about Jason A. Amello’s background, business experience, contracts with TScan Therapeutics, and any related party transactions involving him.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB